Compare NCV & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCV | ATYR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.8M | 83.3M |
| IPO Year | N/A | N/A |
| Metric | NCV | ATYR |
|---|---|---|
| Price | $15.29 | $0.83 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 87.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9,628.95 |
| Revenue Next Year | N/A | $156.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.51 | $0.64 |
| 52 Week High | $16.70 | $7.29 |
| Indicator | NCV | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 43.20 |
| Support Level | $14.84 | $0.82 |
| Resistance Level | $15.65 | $0.85 |
| Average True Range (ATR) | 0.29 | 0.07 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 27.30 | 17.21 |
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).